CALL 347-637-2631 TO JOIN BY PHONE AND ASK QUESTIONS
Teclistamab is the first bispecific antibody to be FDA approved in mulitple myeloma. On this HealthTree Podcast for Multiple Myeloma episode, learn from Alfred Garfall, MD of the University of Pennsylvania about how it will be used in the clinic as an approved therapy.
Our discussion will include who qualifies for this new treatment, when patients should consider using it, if it can be combined with other myeloma therapies, if the therapy is continuous or can be stopped, common side effects to expect, how it is administered (in and outpatient) and how the caregiver needs to be involved.
We appreciate your donations to support the HealthTree Foundation Podcast.
Welcome, Announcements & Introduction
A discussion with Alfred Garfall, MD about the recent approval of teclistamab, the first bispecific antibody in multiple myeloma.
Audience is able to call in to the radio show. Call 347-637-2631 and press 1 on your keypad to ask Dr. Garfall questions about what was discussed during our interview today.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Dr. Garfall is Director of the Autologous Hematopoietic Stem Cell Transplantation program and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113
Support@healthtree.org
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.